Endocrine therapy for breast cancer

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Breast cancer management increasingly utilizes endocrine agents alongside ovarian ablation.
• Available endocrine therapies include antiestrogens, progestational drugs, and aromatase inhibitors.
• These agents are used in both metastatic and adjuvant breast cancer treatment settings.

Purpose of the Study:

• To review the current landscape of endocrine agents for breast cancer.
• To discuss the established roles of endocrine therapies in premenopausal and postmenopausal women.
• To highlight ongoing research into novel endocrine agents and treatment strategies.

Main Methods:

• Review of randomized trials and meta-analyses on endocrine agents for breast cancer.
• Analysis of the efficacy and application of established endocrine therapies.
• Exploration of emerging endocrine agents and their potential mechanisms.

Main Results:

• Established endocrine agents like antiestrogens and aromatase inhibitors have defined roles in breast cancer treatment.
• Bisphosphonates improve quality of life in patients with metastatic breast cancer.
• Optimal sequencing and combination of endocrine therapies remain areas of active investigation.

Conclusions:

• Endocrine therapy is a cornerstone of breast cancer management, with multiple agent classes available.
• Further research is needed to determine the best combination and sequence of endocrine agents.
• Newer agents, including pure antiestrogens and selective estrogen receptor modulators (SERMs), show promise.